AMD Market Disrupto | Clearside Biomedical's CLS-AX aims to revolutionize wet AMD treatment with flexible dosing, potentially addressing a significant unmet need in ophthalmology |
Financial Crossroads | With $20M in cash, Clearside faces funding challenges for pivotal trials. Analyst price targets range from $4 to $8, suggesting significant upside potential |
Innovative Pipeline | Explore CLS-AX's unique product profile, which could allow for personalized treatment regimens and extended dosing intervals beyond the current six-month standard |
Competitive Landscape | Delve into Clearside's position in the lucrative AMD market, where its 91.05% gross profit margin and differentiated approach could provide a competitive edge |
Metrics to compare | CLSDQ | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipCLSDQPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −4.4x | −0.3x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | −0.3x | 2.7x | 2.6x | |
Price / LTM Sales | 5.4x | 5.1x | 3.1x | |
Upside (Analyst Target) | - | 45.4% | 48.3% | |
Fair Value Upside | Unlock | −3.2% | 6.7% | Unlock |